136 results about "Transplanted Organs" patented technology

An implantable system control unit (SCU) includes means for measuring tissue impedance or other condition to determine allograft health, in order to predict or detect allograft rejection. The SCU also includes at least two electrodes coupled to means for delivering electrical stimulation to a patient within whom the device is implanted, and may also include a reservoir for holding one or more drugs and a driver means for delivering the drug(s) to the patient. In certain embodiments, the system is capable of open- and closed-loop operation. In closed-loop operation, at least one SCU includes a sensor, and the sensed condition is used to adjust stimulation parameters. Alternatively, this sensory “SCU” sounds an alarm, communicates an alarm to an external device, and / or is responsive to queries regarding sensed information, such as tissue impedance.

A method for the early diagnosis of breast, lung, pancreatic and colon growths and cancers as well as conditions associated with donor and recipient organ transplants, both before and after transplantation to identify and allow treatment of possible transplanted organ rejection and other disease conditions related and unrelated to the transplantation, compares the gene expression patterns from a patient's peripheral blood monocytes-lymphocyte's gene system with either the similar gene expression patterns of a normal person, or with the similar gene expression patterns of a person known to have the condition being screened for. Differences between the patient's gene expression patterns for particular genes and the normal patterns indicates the presence of the condition with the number of differences indicating the probability of the condition. Similarities between the patient's gene expression patterns for those particular genes and the patterns of a person known to have the condition indicates the presence of the condition with the number of similarities indicating the probability of the condition. For example, particular genes for use in identifying pancreatic cancer are disclosed.

Compositions and methods are described for highly sensitive quantification of the relative representation of DNA from adaptive immune cells (e.g., T and / or B lymphocytes) in DNA extracted from complex mixtures of cells that include cells which are not adaptive immune cells. Included are methods for determining the relative presence in a tumor of tumor infiltrating lymphocytes (TIL), the relative presence of lymphocytes infiltrating a somatic tissue that is the target of an autoimmune disease, and the relative presence of lymphocytes infiltrating a transplanted organ.

An implantable system control unit (SCU) includes means for measuring tissue impedance or other condition to determine allograft health, in order to predict or detect allograft rejection. The SCU also includes at least two electrodes coupled to means for delivering electrical stimulation to a patient within whom the device is implanted, and may also include a reservoir for holding one or more drugs and a driver means for delivering the drug(s) to the patient. In certain embodiments, the system is capable of open- and closed-loop operation. In closed-loop operation, at least one SCU includes a sensor, and the sensed condition is used to adjust stimulation parameters. Alternatively, this sensory “SCU” sounds an alarm, communicates an alarm to an external device, and / or is responsive to queries regarding sensed information, such as tissue impedance.

The invention discloses a sub normal temperature transplanted organ extracorporal intelligent support system and method. The system mainly comprises a sensor acquisition module, a perfusion / oxygenation module, a safety protection module, a man-machine interaction module, a data storage and analysis module, a network module, a power management module and a central control module. According to the invention, intracorporal physiological simulation of full-simulation pulsating wave perfusion, temperature control and oxygenation supply combination is constructed, and various sensors are coordinated to monitor various life indicators, so that multifunctional and multiparameter intelligent storage of an organ is realized. The method is designed according to extracorporal storage characteristics of the transplanted organ and comprises analysis of organ real-time physiological parameter, intelligent feedback adjustment and control of perfusion / oxygenation, failure alarm and safety protection, network data sharing and remote control, and safe and effective long-time storage can be realized. The system adopts the full-simulation pulsating wave perfusion and dynamic simulation feedback control technologies; the perfusion pressure is closer to that of a human body, the parameter adjustment and control are more accurate, and the range is wider.

The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ.

A pharmaceutical preparation comprising a hepatocyte growth factor or a DNA molecule encoding the same and the like according to the present invention can suppress the fibrosis of a transplanted organ after organ transplantation. The present invention is useful in the fields of organ transplantation and regeneration therapy.

A method for the early diagnosis of breast, lung, pancreatic and colon growths and cancers as well as conditions associated with donor and recipient organ transplants, both before and after transplantation to identify and allow treatment of possible transplanted organ rejection and other disease conditions related and unrelated to the transplantation, compares the gene expression patterns from a patient's peripheral blood monocytes-lymphocyte's gene system with either the similar gene expression patterns of a normal person, or with the similar gene expression patterns of a person known to have the condition being screened for. Differences between the patient's gene expression patterns for particular genes and the normal patterns indicates the presence of the condition with the number of differences indicating the probability of the condition. Similarities between the patient's gene expression patterns for those particular genes and the patterns of a person known to have the condition indicates the presence of the condition with the number of similarities indicating the probability of the condition. For example, particular genes for use in identifying pancreatic cancer are disclosed.

Provided are a gold nanorod with surface finish rosinyl quaternary ammonium salt molecules and a preparation method and application thereof. The preparation method comprises a first step of preparation of the rosinyl quaternary ammonium salt molecules, a second step of preparation of gold nanorod solution, a third step of preparation of the gold nanorod with the surface finish rosinyl molecules, wherein the third step comprises the substeps of enabling the obtained 6-7 mL of gold nanorod solution to undergo ultrasonic treatment for 20 min, adding the prepared rosinyl quaternary ammonium salt molecules of 0.014 g, performing ultrasonic treatment, standing the solution for 2-3 days under the water bath conditions of 35-40 DEG C, and finally obtaining the brown red solution which is the 2 mg / mL gold nanorod solution with the surface finish rosinyl quaternary ammonium salt molecules. The gold nanorod with the surface finish rosinyl quaternary ammonium salt molecules has a near-infrared photothermal conversion effect, can be applied to the fields of bacterial resistance, organ transplantation and medical equipment and have biological activities of bacterial resistance and cancer resistance.

Methods for reducing injury to a transplanted mammalian organ or tissue, including inhibiting the development of graft blood vessel disease, are provided. In one form, a method includes administering compositions that include one or more PKC regulators to an organ or tissue donor and an organ or tissue recipient. Methods for decreasing or otherwise modulating an inflammatory response in a mammal are also provided. In one form, a method includes administering one or more regulators of protein kinase C to a patient in need thereof prior to, during or after an event giving rise to an inflammatory response. Methods for inhibiting, or otherwise modulating, a pro-apoptotic event are also provided. In one form, a method includes administering a therapeutically effective amount of an agonist of ε protein kinase C, and optionally an inhibitor of δ protein kinase C.

The compounds of the present invention are represented by the following compounds having Formula (I) where the substituents R1-R10, X, Y, k, m, n, q, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.